Merck Manual

Please confirm that you are a health care professional

honeypot link

Overview of Thrombotic Disorders


Joel L. Moake

, MD, Baylor College of Medicine

Reviewed/Revised Jan 2021 | Modified Sep 2022
View Patient Education
Topic Resources

In healthy people, homeostatic balance Overview of Hemostasis Hemostasis, the arrest of bleeding from an injured blood vessel, requires the combined activity of Vascular factors Platelets Plasma coagulation factors Regulatory mechanisms counterbalance... read more exists between procoagulant (clotting) forces and anticoagulant and fibrinolytic forces. Numerous genetic, acquired, and environmental factors can tip the balance in favor of coagulation, leading to the pathologic formation of thrombi in veins (eg, deep venous thrombosis Deep Venous Thrombosis (DVT) Deep venous thrombosis (DVT) is clotting of blood in a deep vein of an extremity (usually calf or thigh) or the pelvis. DVT is the primary cause of pulmonary embolism. DVT results from conditions... read more Deep Venous Thrombosis (DVT) [DVT]), arteries (eg, myocardial infarction Acute Myocardial Infarction (MI) Acute myocardial infarction is myocardial necrosis resulting from acute obstruction of a coronary artery. Symptoms include chest discomfort with or without dyspnea, nausea, and/or diaphoresis... read more Acute Myocardial Infarction (MI) , ischemic stroke Ischemic Stroke Ischemic stroke is sudden neurologic deficits that result from focal cerebral ischemia associated with permanent brain infarction (eg, positive results on diffusion-weighted MRI). Common causes... read more Ischemic Stroke ), or cardiac chambers. Thrombi can obstruct blood flow at the site of formation or detach and embolize to block a distant blood vessel (eg, pulmonary embolism Pulmonary Embolism (PE) Pulmonary embolism (PE) is the occlusion of pulmonary arteries by thrombi that originate elsewhere, typically in the large veins of the legs or pelvis. Risk factors for pulmonary embolism are... read more Pulmonary Embolism (PE) , embolic stroke).

Etiology of Thrombotic Disorders

Genetic defects that increase the propensity for venous thromboembolism include

Acquired defects also predispose to venous and arterial thrombosis (see table Acquired Causes of Thromboembolism Acquired Causes of Thromboembolism Acquired Causes of Thromboembolism ).

Other disorders and environmental factors can increase the risk of thrombosis, especially if a genetic abnormality is also present.


Symptoms and Signs of Thrombotic Disorders

  • Chest pain and shortness of breath: Possible PE

  • Leg warmth, redness, and swelling: DVT

  • Weakness/numbness of one side of the body, problems speaking, and problems with balance and walking: Possible ischemic stroke

  • Abdominal pain: Possible mesenteric ischemia

Most of the inherited disorders do not begin to cause an increased risk of clotting until young adulthood, although clots can form at any age. Women may have a history of multiple spontaneous abortions Spontaneous Abortion Spontaneous abortion is pregnancy loss before 20 weeks gestation. Threatened abortion is vaginal bleeding without cervical dilation before 20 weeks in a confirmed viable intrauterine pregnancy... read more .

Diagnosis of Thrombotic Disorders

Predisposing factors

Predisposing factors should always be considered. In some cases, the condition is clinically obvious (eg, recent surgery or trauma, prolonged immobilization, cancer, generalized atherosclerosis). If no predisposing factor is readily apparent, further evaluation should be conducted in patients with

  • Family history of venous thrombosis

  • More than one episode of venous thrombosis

  • Venous or arterial thrombosis before age 50

  • Unusual sites of venous thrombosis (eg, cavernous sinus, mesenteric veins)

As many as half of all patients with spontaneous DVT have a genetic predisposition.

Testing for predisposing congenital factors includes specific assays that measure the quantity or activity of natural anticoagulant molecules in plasma, and screening for specific gene defects, as follows:

  • Clotting assay for lupus anticoagulant

  • Clotting assay for resistance to activated protein C

  • Genetic test for factor V Leiden

  • Genetic test for prothrombin gene mutation (G20210A)

  • Functional assay of antithrombin

  • Functional assay of protein C

  • Functional assay of protein S

  • Antigenic assays of total and free protein S.

  • Measurement of plasma homocysteine levels

  • Immunoassays for antiphospholipid antibodies

Treatment of Thrombotic Disorders

Treatment is summarized elsewhere in THE MANUAL specific to the location of the thrombus.

Anticoagulation is often required, typically beginning with parenteral heparin or low molecular weight heparin, and then followed by oral warfarin or one of the direct oral anticoagulants (DOACs). Drugs include factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) and a direct thrombin inhibitor (dabigatran). Unlike warfarin, the direct oral anticoagulants do not require regular laboratory monitoring. DOACs can be reversed either by time (they have brief in vivo half-lives) or in some cases by recently developed agents (idaricizumab for dabigatran; andexanet for rivaroxaban or apixaban [ 1, 2 Treatment references In healthy people, homeostatic balance exists between procoagulant (clotting) forces and anticoagulant and fibrinolytic forces. Numerous genetic, acquired, and environmental factors can tip... read more ]).

A major current disadvantage of DOACs is their expense.

Treatment references

Drugs Mentioned In This Article

Drug Name Select Trade
Hepflush-10 , Hep-Lock, Hep-Lock U/P, Monoject Prefill Advanced Heparin Lock Flush, SASH Normal Saline and Heparin
Coumadin, Jantoven
Xarelto, Xarelto Granules, Xarelto Starter Pack
View Patient Education
NOTE: This is the Professional Version. CONSUMERS: View Consumer Version
quiz link

Test your knowledge

Take a Quiz!